Diagnosis and management of acute myeloid leukemia in children and adolescents: Recommendations from an international expert panel

Blood

Volumn 120, Issue 16, 2012, Pages 3167-3205

  Creutzig, Ursula ^a   Van Den Heuvel Eibrink, Marry M ^b   Gibson, Brenda ^c   Dworzak, Michael N ^d   Adachi, Souichi ^e   De Bont, Eveline ^f   Harbott, Jochen ^g   Hasle, Henrik ^h   Johnston, Donna ⁱ   Kinoshita, Akitoshi ^j   Lehrnbecher, Thomas ^k   Leverger, Guy ^l   Mejstrikova, Ester ^m   Meshinchi, Soheil ^n,o   Pession, Andrea ^p   Raimondi, Susana C ^q   Sung, Lillian ^r   Stary, Jan ^m   Zwaan, Christian M ^b   Kaspers, Gertjan J L ^s   Reinhardt, Dirk ^a   more..

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^c ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e KYOTO UNIVERSITY   (Japan)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g JUSTUS LIEBIG UNIVERSITY   (Germany)

^h AARHUS UNIVERSITY HOSPITAL   (Denmark)

ⁱ CHILDREN S HOSPITAL OF EASTERN ONTARIO   (Canada)

^j ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^k GOETHE UNIVERSITY   (Germany)

^l ARMAND TROUSSEAU HOSPITAL   (France)

^m CHARLES UNIVERSITY   (Czech Republic)

ⁿ UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^o Fred Hutchinson Cancer Research Center   (United States)

^p UNIVERSITY OF BOLOGNA   (Italy)

^q ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^r HOSPITAL FOR SICK CHILDREN   (Canada)

^s VU UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACLARUBICIN; ALKYLATING AGENT; AMSACRINE; ANTHRACYCLINE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FLUCONAZOLE; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; HYDROCORTISONE; IDARUBICIN; ITRACONAZOLE; LESTAURTINIB; METHOTREXATE; MICAFUNGIN; MIDOSTAURIN; MITOXANTRONE; POSACONAZOLE; QUIZARTINIB; RASBURICASE; RAZOXANE; RETINOIC ACID; SORAFENIB; TIOGUANINE; UNINDEXED DRUG; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE TOXICITY; ADOLESCENT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIBIOTIC PROPHYLAXIS; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BLAST CELL; BONE MARROW BIOPSY; BONE MARROW EXAMINATION; BONE MARROW SUPPRESSION; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CELL LINEAGE; CENTRAL NERVOUS SYSTEM LEUKEMIA; CEREBROSPINAL FLUID EXAMINATION; CHILD; CHILDHOOD LEUKEMIA; CONSOLIDATION CHEMOTHERAPY; CONTINUOUS INFUSION; CYTOCHEMISTRY; CYTOGENETICS; DIAGNOSTIC TEST; DIFFERENTIAL DIAGNOSIS; DOSAGE SCHEDULE COMPARISON; DOWN SYNDROME; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MEGADOSE; DRUG SAFETY; EVENT FREE SURVIVAL; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; GENE MUTATION; GENETIC ASSOCIATION; GRANULOCYTIC SARCOMA; GROUPS BY AGE; HEART PROTECTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERLEUKOCYTOSIS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; INVASIVE ASPERGILLOSIS; KARYOTYPING; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LUMBAR PUNCTURE; METASTASIS; MIXED PHENOTYPE ACUTE LEUKEMIA; MOLECULAR GENETICS; MULTIPLE CYCLE TREATMENT; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VEIN OCCLUSION; WHOLE BODY RADIATION; ADULT; COMPARATIVE STUDY; DISEASE MANAGEMENT; PRACTICE GUIDELINE; STANDARD;

ADOLESCENT; ADULT; CHILD; DISEASE MANAGEMENT; HUMANS; LEUKEMIA, MYELOID, ACUTE; PRACTICE GUIDELINES AS TOPIC;

EID: 84868129082     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-03-362608     Document Type: Review

References (225)

1. Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol. 1990;8(5):813-819. (Pubitemid 20148273)
2. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21(24):4642-4649. (Pubitemid 46594039)
3. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumors of Haemtopoetic and Lymphoid Tissues. Lyon, France: International Agency for Research on Cancer; 2008.
4. Döhner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951.
6. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias: European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783-1786.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-M0). Br J Haematol. 1991;78:325-329.
8. Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia. 2003;17(2):277-282. (Pubitemid 36266902)
9. Bene MC, Nebe T, Bettelheim P, et al. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European Leukemia Net Work Package 10. Leukemia. 2011;25(4):567-574.
10. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6):543-552.
11. Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72(Suppl 1):S14-S22. (Pubitemid 350194344)
12. Betts DR, Ammann RA, Hirt A, et al. The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia: a study of the Swiss Paediatric Oncology Group (SPOG). Eur J Haematol. 2007;78(6):468-476. (Pubitemid 46753600)
13. Grimwade D. The clinical significance of cytogenetic abnormalities in acute myeloid leukaemia. Best Pract Res Clin Haematol. 2001;14(3):497-529. (Pubitemid 33019748)
14. Harrison CJ, Hills RK, Moorman AV, et al. Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12. J Clin Oncol. 2010;28(16):2674-2681.
15. von Neuhoff C, Reinhardt D, Sander A, et al. Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98. J Clin Oncol. 2010;28(16):2682-2689.
16. Mercher T, Busson-Le Coniat M, Nguyen KF, et al. Recurrence of OTT-MAL fusion in t (1;22) of infant AML-M7. Genes Chromosomes Cancer. 2002;33(1):22-28.
17. Torres L, Lisboa S, Vieira J, et al. Acute megakaryoblastic leukemia with a four-way variant translocation originating the RBM15-MKL1 fusion gene. Pediatr Blood Cancer. 2011;56(5):846-849.
18. Park J, Kim M, Lim J, et al. Three-way complex translocations in infant acute myeloid leukemia with t (7;12) (q36;p13): the incidence and correlation of a HLXB9 overexpression. Cancer Genet Cytogenet. 2009;191(2):102-105.
19. Simmons HM, Oseth L, Nguyen P, O'Leary M, Conklin KF, Hirsch B. Cytogenetic and molecular heterogeneity of 7q36/12p13 rearrangements in childhood AML. Leukemia. 2002;16(12):2408-2416. (Pubitemid 36054375)
20. Slater RM, von Drunen E, Kroes WG, et al. t (7; 12) (q36;p13) and t (7;12) (q32;p13)-translocations involving ETV6 in children 18 months of age or younger with myeloid disorders. Leukemia. 2001;15(6):915-920. (Pubitemid 32529891)
21. von Bergh AR, van Drunen E, van Wering ER, et al. High incidence of t (7;12) (q36;p13) in infant AML but not in infant ALL, with a dismal outcome and ectopic expression of HLXB9. Genes Chromosomes Cancer. 2006;45(8):731-739.
22. Hollink IH, Van den Heuvel-Eibrink MM, Arentsen-Peters ST, et al. NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern. Blood. 2011;118(13):3645-3656.
23. Hasle H, Alonzo TA, Auvrignon A, et al. Monosomy 7 and deletion 7q in children and adolescents with acute myeloid leukemia: an international retrospective study. Blood. 2007;109(11):4641-4647. (Pubitemid 46827753)
24. Breems DA, Van Putten WL, De Greef GE, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-4797.
25. Creutzig U, Buchner T, Sauerland MC, et al. Significance of age in acute myeloid leukemia patients younger than 30 years. Cancer. 2008;112(3):562-571.
26. Gilliland DG. Molecular genetics of human leukemias: new insights into therapy. Semin Hematol. 2002;39(4 Suppl 3):6-11. (Pubitemid 35417143)
27. Balgobind BV, Hollink IH, Arentsen-Peters ST, et al. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia. Haematologica. 2011;96(10):1478-1487.
28. Ho PA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2009;113(26):6558-6566.
29. Hollink IH, Zwaan CM, Zimmermann M, et al. Favorable prognostic impact of NPM1 gene mutations in childhood acute myeloid leukemia, with emphasis on cytogenetically normal AML. Leukemia. 2009;23(2):262-270.
30. Meshinchi S, Alonzo TA, Stirewalt DL, et al. Clinical implications of FLT3 mutations in pediatric AML. Blood. 2006;108(12):3654-3661. (Pubitemid 44864541)
31. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011;29(5):551-565.
32. Brown P, McIntyre E, Rau R, et al. The incidence and clinical significance of nucleophosmin mutations in childhood AML. Blood. 2007;110(3):979-985. (Pubitemid 47267437)
33. Thiede C, Creutzig E, Reinhardt D, Ehninger G, Creutzig U. Different types of NPM1 mutations in children and adults: evidence for an effect of patient age on the prevalence of the TCTG-tandem duplication in NPM1-exon 12. Leukemia. 2007;21(2):366-367. (Pubitemid 46158137)
34. Cazzaniga G, Dell'Oro MG, Mecucci C, et al. Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. Blood. 2005;106(4):1419-1422. (Pubitemid 41129610)
35. Balgobind BV, Van den Heuvel-Eibrink MM, De Menezes RX, et al. Evaluation of gene expression signatures predictive of cytogenetic and molecular subtypes of pediatric acute myeloid leukemia. Haematologica. 2011;96(2):221-230.
36. Ho PA, Zeng R, Alonzo TA, et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group. Blood. 2010;116(5):702-710.
37. Hollink IH, Van den Heuvel-Eibrink MM, Zimmermann M, et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood. 2009;113(23):5951-5960.
38. Meshinchi S, Appelbaum FR. Structural and functional alterations of FLT3 in acute myeloid leukemia. Clin Cancer Res. 2009;15(13):4263-4269.
39. Berman JN, Gerbing RB, Alonzo TA, et al. Prevalence and clinical implications of NRAS mutations in childhood AML: a report from the Children's Oncology Group. Leukemia. 2011;25(6):1039-1042.
40. Boissel N, Leroy H, Brethon B, et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia. 2006;20(6):965-970. (Pubitemid 43797286)
41. Shih LY, Liang DC, Huang CF, et al. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples. Leukemia. 2008;22(2):303-307.
42. Loh ML, Reynolds MG, Vattikuti S, et al. PTPN11 mutations in pediatric patients with acute myeloid leukemia: results from the Children's Cancer Group. Leukemia. 2004;18(11):1831-1834. (Pubitemid 39530013)
43. Goemans BF, Zwaan CM, Miller M, et al. Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia. Leukemia. 2005;19(9):1536-1542. (Pubitemid 43090396)
44. Pollard JA, Alonzo TA, Gerbing RB, et al. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML. Blood. 2010;115(12):2372-2379.
45. Balgobind BV, Hollink IH, Reinhardt D, et al. Low frequency of MLL-partial tandem duplications in paediatric acute myeloid leukaemia using MLPA as a novel DNA screenings technique. Eur J Cancer. 2010;46(10):1892-1899.
46. Balgobind BV, Lugthart S, Hollink IH, et al. EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia. Leukemia. 2010;24(5):942-949.
47. Staffas A, Kanduri M, Hovland R, et al. Presence of FLT3-ITD and high BAALC expression are independent prognostic markers in childhood acute myeloid leukemia. Blood. 2011;118(22):5905-5913.
48. Damm F, Thol F, Hollink I, et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups. Leukemia. 2011;25(11):1704-1710.
49. Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2011;57(2):204-209.
50. Hollink IH, Feng Q, Danen-van Oorschot AA, et al. Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model. Leukemia. 2012;26(2):371-373.
51. Mardis ER, Ding L, Dooling DJ, et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med. 2009;361(11):1058- 1066.
52. Thol F, Damm F, Ludeking A, et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol. 2011;29(21):2889-2896.
53. Ross ME, Mahfouz R, Onciu M, et al. Gene expression profiling of pediatric acute myelogenous leukemia. Blood. 2004;104(12):3679-3687. (Pubitemid 39564445)
54. Creutzig U, Zimmermann M, Bourquin J-P, et al. Favorable outcome in infants with AML after intensive first-and second-line treatment: an AMLBFM study group report. Leukemia. 2012;26(4):654-661.
55. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104(3):630-639. (Pubitemid 29119294)
56. Balgobind BV, Raimondi SC, Harbott J, et al. Novel prognostic subgroups in childhood 11q23 MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood. 2009;114(12):2489-2496.
57. Coenen EA, Zwaan CM, Meyer C, et al. KIAA1524: a novel MLL translocation partner in acute myeloid leukemia. Leuk Res. 2011;35(1):133-135.
58. Noronha SA, Farrar JE, Alonzo TA, et al. WT1 expression at diagnosis does not predict survival in pediatric AML: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2009;53(6):1136-1139.
59. Abrahamsson J, Forestier E, Heldrup J, et al. Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. J Clin Oncol. 2011;29(3):310-315.
60. Creutzig U, Zimmermann M, Ritter J, et al. Definition of a standard-risk group in children with AML. Br J Haematol. 1999;104:630-639. (Pubitemid 29119294)
61. Wheatley K, Burnett AK, Goldstone AH, et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial: United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol. 1999;107(1):69-79. (Pubitemid 29500811)
62. Langebrake C, Creutzig U, Dworzak M, et al. Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group. J Clin Oncol. 2006;24(22):3686-3692. (Pubitemid 46630545)
63. Van der Velden V, Sluijs-Geling A, Gibson BE, et al. Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRCAML12 protocol. Leukemia. 2010;24(9):1599-1606.
64. Viehmann S, Teigler-Schlegel A, Bruch J, Langebrake C, Reinhardt D, Harbott J. Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RTPCR) in childhood acute myeloid leukemia with AML1/ETO rearrangement. Leukemia. 2003;17(6):1130-1136. (Pubitemid 36722244)
65. Ommen HB, Schnittger S, Jovanovic JV, et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood. 2010;115(2):198-205.
66. Alford KA, Reinhardt K, Garnett C, et al. Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011;118(8):2222-2238.
67. Wells RJ, Woods WG, Lampkin BC, et al. Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: a report from the Childrens Cancer Group. J Clin Oncol. 1993;11(3):538-545. (Pubitemid 23071053)
68. Perel Y, Auvrignon A, Leblanc T, et al. Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. J Clin Oncol. 2002;20(12):2774-2782. (Pubitemid 34651505)
69. Estey E, Dohner H. Acute myeloid leukaemia. Lancet. 2006;368(9550):1894- 1907. (Pubitemid 44794525)
70. Lowenberg B, Griffin JD, Tallman MS. Acute myeloid leukemia and acute promyelocytic leukemia. Hematology Am Soc Hematol Educ Program. 2003;2003:82-101.
71. Woods WG, Kobrinsky N, Buckley JD, et al. Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children's Cancer Group. Blood. 1996;87(12):4979-4989. (Pubitemid 26189839)
72. Kaspers GJ. Pediatric acute myeloid leukemia. Expert Rev Anticancer Ther. 2012;12(3):405-413.
73. Fernandez HF, Sun Z, Yao X, et al. Anthracycline dose intensification in acute myeloid leukemia. N Engl J Med. 2009;361(13):1249-1259.
74. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med. 2009;361(13):1235-1248.
75. van Dalen EC, van der Pal HJ, Caron HN, Kremer LC. Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2009(4):CD005008.
76. van Dalen EC, Michiels EM, Caron HN, Kremer LC. Different anthracycline derivates for reducing cardiotoxicity in cancer patients. Cochrane Database Syst Rev. 2010(3):CD005006.
77. Kremer LC, van der Pal HJ, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol. 2002;13(6):819-829. (Pubitemid 34752678)
78. Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol. 1998;25(4 Suppl 10):72-85. (Pubitemid 28460388)
79. Bielack SS, Erttmann R, Kempf-Bielack B, Winkler K. Impact of scheduling on toxicity and clinical efficacy of doxorubicin: what do we know in the mid-nineties? Eur J Cancer. 1996;32A(10):1652-1660. (Pubitemid 26306872)
80. Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol. 2002;20(6):1677-1682. (Pubitemid 34260550)
81. Smith LA, Cornelius VR, Plummer CJ, et al. Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and metaanalysis of randomised controlled trials. BMC Cancer. 2010;10:337.
82. Creutzig U, Ritter J, Zimmermann M, et al. Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group. Leukemia. 2001;15(3):348-354. (Pubitemid 32243767)
83. Gibson BE, Webb DK, Howman AJ, De Graaf SS, Harrison CJ, Wheatley K. Results of a randomized trial in children with acute myeloid leukaemia: Medical Research Council AML12 trial. Br J Haematol. 2011;155(3):366-376.
84. Lipshultz SE, Alvarez JA, Scully RE. Anthracycline associated cardiotoxicity in survivors of childhood cancer. Heart. 2008;94(4):525-533. (Pubitemid 351441417)
85. U. S. Food and Drug Administration. FDA statement on dexrazoxane. http://www.fda.gov/DrugsDrugSafety/ucm263729.htm. Accessed July 20, 2011.
86. Burnett AK, Hills RK, Milligan DW, et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol. 2010;28(4):586-595.
87. Creutzig U, Zimmermann M, Bourquin JP, et al. Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t (8;21) and with inv (16). Blood. 2011;118(20):5409-5415.
88. Arlin Z, Case DC Jr, Moore J, et al. Randomized multicenter trial of cytosine arabinoside with mitoxantrone or daunorubicin in previously untreated adult patients with acute nonlymphocytic leukemia (ANLL): Lederle Cooperative Group. Leukemia. 1990;4(3):177-183. (Pubitemid 20099889)
89. Michel G, Baruchel A, Tabone MD, et al. Induction chemotherapy followed by allogeneic bone marrow transplantation or aggressive consolidation chemotherapy in childhood acute myeloblastic leukemia: a prospective study from the French Society of Pediatric Hematology and Immunology (SHIP). Hematol Cell Ther. 1996;38(2):169-176.
90. Krance RA, Hurwitz CA, Head DR, et al. Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases. J Clin Oncol. 2001;19(11):2804-2811. (Pubitemid 32538188)
91. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia: Cancer and Leukemia Group B. N Engl J Med. 1994;331(14):896-903. (Pubitemid 24299870)
92. Bloomfield CD, Lawrence D, Byrd JC, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58(18):4173-4179. (Pubitemid 28440576)
93. Lie SO, Abrahamsson J, Clausen N, et al. Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHOAML trials. Br J Haematol. 2003;122(2):217-225. (Pubitemid 36859606)
94. Gibson BE, Wheatley K, Hann IM, et al. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia. 2005;19(12):2130-2138. (Pubitemid 41741605)
95. Stevens RF, Hann IM, Wheatley K, Gray RG. Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial: MRC Childhood Leukaemia Working Party. Br J Haematol. 1998;101(1):130-140. (Pubitemid 28197786)
96. Creutzig U, Zimmermann M, Dworzak M, et al. Study AML-BFM 2004: improved survival in childhood acute myeloid leukemia without increased toxicity [abstract]. Blood (ASH Annual Meeting Abstracts). 2010;116(21):Abstract 181.
97. Tsukimoto I, Tawa A, Horibe K, et al. Riskstratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2009;27(24):4007-4013.
98. Alonzo TA, Wells RJ, Woods WG, et al. Postremission therapy for children with acute myeloid leukemia: the Children's Cancer Group experience in the transplant era. Leukemia. 2005;19(6):965-970. (Pubitemid 40862006)
99. Oliansky DM, Rizzo JD, Aplan PD, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. Biol Blood Marrow Transplant. 2007;13(1):1-25. (Pubitemid 46054985)
100. Ravindranath Y, Yeager AM, Chang MN, et al. Autologous bone marrow transplantation versus intensive consolidation chemotherapy for acute myeloid leukemia in childhood: Pediatric Oncology Group. N Engl J Med. 1996;334(22):1428-1434. (Pubitemid 26157438)
101. Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood. 2001;97(1):56-62. (Pubitemid 32061242)
102. Sanz MA, Grimwade D, Tallman MS, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood. 2009;113(9):1875-1891.
103. Horan JT, Alonzo TA, Lyman GH, et al. Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. J Clin Oncol. 2008;26(35):5797-5801.
104. Klingebiel T, Reinhardt D, Bader P. Place of HSCT in treatment of childhood AML. Bone Marrow Transplant. 2008;42(Suppl 2):S7-S9.
105. Niewerth D, Creutzig U, Bierings MB, Kaspers GJ. A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. Blood. 2010;116(13):2205-2214.
106. Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia. 2005;19(12):2082-2089. (Pubitemid 41741600)
107. Bhatia S. Long-term health impacts of hematopoietic stem cell transplantation inform recommendations for follow-up. Expert Rev Hematol. 2011;4(4):437-452.
108. Bresters D, van Gils IC, Kollen WJ, et al. High burden of late effects after haematopoietic stem cell transplantation in childhood: a single-centre study. Bone Marrow Transplant. 2010;45(1):79-85.
109. Gupta T, Kannan S, Dantkale V, Laskar S. Cyclophosphamide plus total body irradiation compared with busulfan plus cyclophosphamide as a conditioning regimen prior to hematopoietic stem cell transplantation in patients with leukemia: a systematic review and meta-analysis. Hematol Oncol Stem Cell Ther. 2011;4(1):17-29.
110. Appelbaum FR. Optimising the conditioning regimen for acute myeloid leukaemia. Best Pract Res Clin Haematol. 2009;22(4):543-550.
111. Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood. 2001;98(13):3569-3574.
112. Appelbaum FR. Hematopoietic cell transplantation from unrelated donors for treatment of patients with acute myeloid leukemia in first complete remission. Best Pract Res Clin Haematol. 2007;20(1):67-75.
113. Walter RB, Gooley TA, Wood BL, et al. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011;29(9):1190-1197.
114. Bonanomi S, Connor P, Webb D, et al. Successful outcome of allo-SCT in high-risk pediatric AML using chemotherapy-only conditioning and post transplant immunotherapy. Bone Marrow Transplant. 2008;42(4):253-257.
115. Creutzig U, Zimmermann M, Bourquin JP, et al. CNS irradiation in pediatric acute myleoid leukemia: equal results by 12 or 18 Gy in studies AMLBFM98 and 2004. Pediatr Blood Cancer. 2011;57(6):986-992.
116. Dahl GV, Simone JV, Hustu HO, Mason C. Preventive central nervous system irradiation in children with acute nonlymphocytic leukemia. Cancer. 1978;42(5):2187-2192. (Pubitemid 9125874)
117. Creutzig U, Ritter J, Zimmermann M, Schellong G. Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87. J Clin Oncol. 1993;11(2):279-286. (Pubitemid 23046818)
118. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008;9(3):257-268. (Pubitemid 351722945)
119. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. The presence of central nervous system disease at diagnosis in pediatric acute myeloid leukemia does not affect survival: a Children's Oncology Group study. Pediatr Blood Cancer. 2010;55(3):414-420.
120. Pession A. The open issue of central nervous system disease in pediatric acute myeloid leukemia. Pediatr Blood Cancer. 2010;55(3):399-400.
121. Abbott BL, Rubnitz JE, Tong X, et al. Clinical significance of central nervous system involvement at diagnosis of pediatric acute myeloid leukemia: a single institution's experience. Leukemia. 2003;17(11):2090-2096. (Pubitemid 37428372)
122. Mayadev JS, Douglas JG, Storer BE, Appelbaum FR, Storb R. Impact of cranial irradiation added to intrathecal conditioning in hematopoietic cell transplantation in adult acute myeloid leukemia with central nervous system involvement. Int J Radiat Oncol Biol Phys. 2011;80(1):193-198.
123. Johnston DL, Alonzo TA, Gerbing RB, Lange BJ, Woods WG. Risk factors and therapy for isolated central nervous system relapse of pediatric acute myeloid leukemia. J Clin Oncol. 2005;23(36):9172-9178.
124. Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol. 2010;28(15):2591-2597.
125. Lee YJ, Moon JH, Kim JG, et al. Prospective randomization trial of G-CSF-primed induction regimen versus standard regimen in patients with AML. Chonnam Med J. 2011;47(2):80-84.
126. Lowenberg B, van Putten W, Theobald M, et al. Effect of priming with granulocyte colonystimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med. 2003;349(8):743-752. (Pubitemid 37010778)
127. Periclou AP, Avramis VI. NONMEM population pharmacokinetic studies of cytosine arabinoside after high-dose and after loading bolus followed by continuous infusion of the drug in pediatric patients with leukemias. Cancer Chemother Pharmacol. 1996;39(1):42-50. (Pubitemid 26400659)
128. van den Berg H, Hopman AH, Kraakman KC, de Jong D. Spontaneous remission in congenital leukemia is not related to (mosaic) trisomy 21: case presentation and literature review. Pediatr Hematol Oncol. 2004;21(2):135-144. (Pubitemid 38313729)
129. Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426-437.
130. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
131. Reinhardt D, Creutzig U. Isolated myelosarcoma in children-update and review. Leuk Lymphoma. 2002;43(3):565-574.
132. Felice MS, Zubizarreta PA, Alfaro EM, et al. Good outcome of children with acute myeloid leukemia and t (8;21) (q22;q22), even when associated with granulocytic sarcoma: a report from a single institution in Argentina. Cancer. 2000;88(8):1939-1944. (Pubitemid 30213005)
133. Matutes E, Pickl WF, Van't Veer M, et al. Mixedphenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. Blood. 2011;117(11):3163-3171.
134. Gerr H, Zimmermann M, Schrappe M, et al. Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations. Br J Haematol. 2010;149(1):84-92.
135. Mejstrikova E, Volejnikova J, Fronkova E, et al. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria. Haematologica. 2010;95(6):928-935.
136. Miller DR, Miller LP. Acute lymphoblastic leukemia in children: an update of clinical, biological, and therapeutic aspects. Crit Rev Oncol Hematol. 1990;10(2):131-164. (Pubitemid 20233503)
137. Gamis AS, Alonzo TA, Gerbing RB, et al. Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood. 2011;118(26):6752-6759.
138. Hitzler JK, Cheung J, Li Y, Scherer SW, Zipursky A. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome. Blood. 2003;101(11):4301-4304. (Pubitemid 36857793)
139. Wechsler J, Greene M, McDevitt MA, et al. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome. Nat Genet. 2002;32(1):148-152. (Pubitemid 34977210)
140. Li Z, Godinho FJ, Klusmann JH, Garriga-Canut M, Yu C, Orkin SH. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1. Nat Genet. 2005;37(6):613-619. (Pubitemid 40770416)
141. Klusmann JH, Creutzig U, Zimmermann M, et al. Treatment and prognostic impact of transient leukemia in neonates with Down's syndrome. Blood. 2008;111(6):2991-2998.
142. Creutzig U, Reinhardt D, Diekamp S, Dworzak M, Stary J, Zimmermann M. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity. Leukemia. 2005;19(8):1355-1360. (Pubitemid 41136328)
143. Kudo K, Hama A, Kojima S, et al. Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy. Int J Hematol. 2010;91(4):630-635.
144. Kudo K, Kojima S, Tabuchi K, et al. Prospective study of a pirarubicin, intermediate-dose cytarabine, and etoposide regimen in children with Down syndrome and acute myeloid leukemia: the Japanese Childhood AML Cooperative Study Group. J Clin Oncol. 2007;25(34):5442-5447. (Pubitemid 350232221)
145. Zwaan CM, Kaspers GJ, Pieters R, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome. Blood. 2002;99(1):245-251.
146. Taub JW, Ge Y. Down syndrome, drug metabolism and chromosome 21. Pediatr Blood Cancer. 2005;44(1):33-39. (Pubitemid 39602563)
147. Li FP, Bader JL. Epidemiology of cancer in childhood. In: Nathan DG, Oski FA, eds. Hematology of Infancy and Childhood. Philadelphia, PA: Saunders; 1993: 1102-1119.
148. Belson M, Kingsley B, Holmes A. Risk factors for acute leukemia in children: a review. Environ Health Perspect. 2007;115(1):138-145. (Pubitemid 46050296)
149. Mehta PA, Ileri T, Harris RE, et al. Chemotherapy for myeloid malignancy in children with Fanconi anemia. Pediatr Blood Cancer. 2007;48(7):668-672. (Pubitemid 46717613)
150. Stelljes M, Corbacioglu A, Schlenk RF, et al. Allogeneic stem cell transplant to eliminate germline mutations in the gene for CCAAT-enhancer- binding protein alpha from hematopoietic cells in a family with AML. Leukemia. 2011;25(7):1209-1210.
151. Gregory J, Feusner J. Acute promyelocytic leukemia in childhood. Curr Oncol Rep. 2009;11(6):439-445.
152. Mann G, Reinhardt D, Ritter J, et al. Treatment with all-trans retinoic acid in acute promyelocytic leukemia reduces early deaths in children. Ann Hematol. 2001;80(7):417-422. (Pubitemid 32725460)
153. de Botton S, Coiteux V, Chevret S, et al. Outcome of childhood acute promyelocytic leukemia with all-trans-retinoic acid and chemotherapy. J Clin Oncol. 2004;22(8):1404-1412. (Pubitemid 41103622)
154. Ortega JJ, Madero L, Martin G, et al. Treatment with all-trans retinoic acid and anthracycline monochemotherapy for children with acute promyelocytic leukemia: a multicenter study by the PETHEMA Group. J Clin Oncol. 2005;23(30):7632-7640. (Pubitemid 46291827)
155. Testi AM, Biondi A, Lo CF, et al. GIMEMAAIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447-453. (Pubitemid 40981236)
156. Asou N, Kishimoto Y, Kiyoi H, et al. A randomized study with or without intensified maintenance chemotherapy in patients with acute promyelocytic leukemia who have become negative for PML-RARalpha transcript after consolidation therapy: the Japan Adult Leukemia Study Group (JALSG) APL97 study. Blood. 2007;110(1):59-66. (Pubitemid 47026819)
157. Sanz MA, Martin G, Rayon C, et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML RARalpha-positive acute promyelocytic leukemia: PETHEMA group. Blood. 1999;94(9):3015-3021. (Pubitemid 29512705)
158. Creutzig U, Zimmermann M, Dworzak M, et al. Favourable outcome of patients with childhood acute promyelocytic leukaemia after treatment with reduced cumulative anthracycline doses. Br J Haematol. 2010;149(3):399-409.
159. Lo-Coco F, Ammatuna E. Front line clinical trials and minimal residual disease monitoring in acute promyelocytic leukemia. Curr Top Microbiol Immunol. 2007;313:145-156. (Pubitemid 47400337)
160. Grimwade D, Jovanovic JV, Hills RK, et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol. 2009;27(22):3650- 3658.
161. Zhou J, Zhang Y, Li J, et al. Single-agent arsenic trioxide in the treatment of children with newly diagnosed acute promyelocytic leukemia. Blood. 2010;115(9):1697-1702.
162. Estey E, Garcia-Manero G, Ferrajoli A, et al. Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia. Blood. 2006;107(9):3469-3473.
163. Larson RA. Etiology and management of therapyrelated myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007;2007:453-459.
164. Pui CH, Raimondi SC, Head DR, et al. Characterization of childhood acute leukemia with multiple myeloid and lymphoid markers at diagnosis and at relapse. Blood. 1991;78(5):1327-1337.
165. Aguilera DG, Vaklavas C, Tsimberidou AM, Wen S, Medeiros LJ, Corey SJ. Pediatric therapy-related myelodysplastic syndrome/acute myeloid leukemia: the M. D. Anderson Cancer Center experience. J Pediatr Hematol Oncol. 2009;31(11):803-811.
166. Kaspers GJ, Creutzig U. Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 2005;19(12):2025-2029. (Pubitemid 41741594)
167. Sander A, Zimmermann M, Dworzak M, et al. Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials. Leukemia. 2010;24(8):1422-1428.
168. Stahnke K, Boos J, Bender-Gotze C, Ritter J, Zimmermann M, Creutzig U. Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia. 1998;12(10):1534-1538. (Pubitemid 28470436)
169. Kaspers GJL, Zimmermann M, Reinhardt D, et al. Addition of liposomal daunorubicin (DaunoXome) to FLAG significantly improves treatment response in pediatric relapsed AML: final results from the International Randomised Phase III Study Relapsed AML 2001/01 [abstract]. Blood (ASH Annual Meeting Abstracts). 2009;114(22):Abstract 18.
170. Abrahamsson J, Clausen N, Gustafsson G, et al. Improved outcome after relapse in children with acute myeloid leukaemia. Br J Haematol. 2007;136(2):229-236. (Pubitemid 46020750)
171. Webb DK, Wheatley K, Harrison G, Stevens RF, Hann IM. Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial: MRC Childhood Leukaemia Working Party. Leukemia. 1999;13(1):25-31. (Pubitemid 29043713)
172. Gandhi V, Estey E, Keating MJ, Plunkett W. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11(1):116-124. (Pubitemid 23059984)
173. Goemans BF, Tamminga RY, Corbijn CM, Hahlen K, Kaspers GJ. Outcome for children with relapsed acute myeloid leukemia in The Netherlands following initial treatment between 1980 and 1998: survival after chemotherapy only? Haematologica. 2008;93(9):1418-1420.
174. Burnett AK, Hills RK, Milligan D, et al. Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. J Clin Oncol. 2011;29(4):369-377.
175. Zwaan CM, Reinhardt D, Zimmerman M, et al. Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study. Br J Haematol. 2010;148(5):768-776.
176. Jeha S, Razzouk B, Rytting M, et al. Phase II study of clofarabine in pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Oncol. 2009;27(26):4392-4397.
177. Hijiya N, Gaynon P, Barry E, et al. A multi-center phase I study of clofarabine, etoposide and cyclophosphamide in combination in pediatric patients with refractory or relapsed acute leukemia. Leukemia. 2009;23(12):2259-2264.
178. Sievers EL, Larson RA, Stadtmauer EA, et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol. 2001;19(13):3244-3254. (Pubitemid 32591442)
179. Zwaan CM, Reinhardt D, Corbacioglu S, et al. Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis. Blood. 2003;101(10):3868-3871. (Pubitemid 36857859)
180. Delaunay J, Recher C, Pigneux A, et al. Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic rransplantation: results of the GOELAMS AML 2006 IR Study [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 79.
181. Brethon B, Yakouben K, Oudot C, et al. Efficacy of fractionated gemtuzumab ozogamicin combined with cytarabine in advanced childhood myeloid leukaemia. Br J Haematol. 2008;143(4):541-547.
182. Reinhardt D, Diekamp S, Fleischhack G, et al. Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia. Onkologie. 2004;27(3):269-272. (Pubitemid 39279336)
183. Burnett AK, Hills RK, Hunter AE, et al. The addition of gemtuzumab ozogamicin to intensive chemotherapy in older patients with AML produces a significant improvement in overall survival: results of the UK NCRI AML16 Randomized Trial [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 582.
184. Castaigne S, Pautas C, Terre C, et al. Fractionated doses of gemtuzumab ozogamicin (GO) combined to standard chemotherapy (CT) improve event-free and overall survival in newly-diagnosed de novo AMLpatients aged 50-70 years old: a prospective randomized phase 3 trial from the Acute Leukemia French Association (ALFA) [abstract]. Blood (ASH Annual Meeting Abstracts). 2011;118(21):Abstract 6.
185. Castaigne S, Pautas C, Terre C, et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012;379(9825):1508-1516.
186. Cooper TM, Franklin J, Gerbing RB, et al. AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group. Cancer. 2012;118(3):761-769.
187. Fathi A, Levis M. FLT3 inhibitors: a story of the old and the new. Curr Opin Hematol. 2011;18(2):71-76.
188. Inaba H, Rubnitz JE, Coustan-Smith E, et al. Phase I pharmacokinetic and pharmacodynamic study of the multikinase inhibitor sorafenib in combination with clofarabine and cytarabine in pediatric relapsed/refractory leukemia. J Clin Oncol. 2011;29(24):3293-3300.
189. Creutzig U, Ritter J, Budde M, Sutor A, Schellong G. Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia: associations with hyperleukocytosis and acute monocytic leukemia. Cancer. 1987;60(12):3071-3079. (Pubitemid 18013184)
190. Inaba H, Fan Y, Pounds S, et al. Clinical and biologic features and treatment outcome of children with newly diagnosed acute myeloid leukemia and hyperleukocytosis. Cancer. 2008;113(3):522-529.
191. Malaguarnera G, Giordano M, Malaguarnera M. Rasburicase for the treatment of tumor lysis in hematological malignancies. Expert Rev Hematol. 2012;5(1):27-38.
192. Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356(4):348-359. (Pubitemid 46148777)
193. Lehrnbecher T, Groll AH. Invasive fungal infections in the pediatric population. Expert Rev Anti Infect Ther. 2011;9(3):275-278.
194. Hughes WT, Kuhn S, Chaudhary S, et al. Successful chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1977;297(26):1419-1426.
195. Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L. Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med. 1987;316(26):1627-1632. (Pubitemid 17082589)
196. Sung L, Nathan PC, Alibhai SM, Tomlinson GA, Beyene J. Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection. Ann Intern Med. 2007;147(6):400-411. (Pubitemid 351664541)
197. Gamis AS, Howells WB, De Swarte-Wallace J, Feusner JH, Buckley JD, Woods WG. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's Cancer Group Study CCG-2891. J Clin Oncol. 2000;18(9):1845-1855. (Pubitemid 30261922)
198. Kurt B, Flynn P, Shenep JL, et al. Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer. 2008;113(2):376-382.
199. Gafter-Gvili A, Fraser A, Paul M, et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev. 2012;1:CD004386.
200. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56-e93.
201. van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005;41(10):1372-1382. (Pubitemid 40826460)
202. Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005;142(12):979-995. (Pubitemid 40840313)
203. Lehrnbecher T, Ethier MC, Zaoutis T, et al. International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol. 2009;147(1):125-128.
204. Lehrnbecher T, Zimmermann M, Reinhardt D, Dworzak M, Stary J, Creutzig U. Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia. Blood. 2007;109(3):936-943. (Pubitemid 46220636)
205. Schaison G, Eden OB, Henze G, et al. Recommendations on the use of colony-stimulating factors in children: conclusions of a European panel. Eur J Pediatr. 1998;157(12):955-966. (Pubitemid 28559744)
206. Dores GM, Devesa SS, Curtis RE, Linet MS, Morton LM. Acute leukemia incidence and patient survival among children and adults in the United States, 2001-2007. Blood. 2012;119(1):34-43.
207. Strahm B, Nollke P, Zecca M, et al. Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome in children: results of the EWOG-MDS 98 study. Leukemia. 2011;25(3):455-462.
208. Wandt H, Schakel U, Kroschinsky F, et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood. 2008;111(4):1855-1861. (Pubitemid 351451493)
209. Grimwade D, Walker H, Oliver F, et al. What happens subsequently in AML when cytogenetic abnormalities persist at bone marrow harvest? Results of the 10th UK MRC AML trial. Medical Research Council Leukaemia Working Parties. Bone Marrow Transplant. 1997;19(11):1117-1123. (Pubitemid 27267736)
210. Smith ML, Hills RK, Grimwade D. Independent prognostic variables in acute myeloid leukaemia. Blood Rev. 2011;25(1):39-51.
211. Dohner K, Dohner H. Molecular characterization of acute myeloid leukemia. Haematologica. 2008;93(7):976-982. (Pubitemid 351957013)
212. Haferlach T, Bacher U, Haferlach C, Kern W, Schnittger S. Insight into the molecular pathogenesis of myeloid malignancies. Curr Opin Hematol. 2007;14(2):90-97. (Pubitemid 46175092)
213. Schlenk RF, Ganser A, Dohner K. Prognostic and predictive effect of molecular and cytogenetic aberrations in acute myeloid leukemia. ASCO Educ Book. 2010;228-232.
214. Dohner H, Gaidzik VI. Impact of genetic features on treatment decisions in AML. Hematology Am Soc Hematol Educ Program. 2011;2011(1):36-42.
215. de Jonge HJ, Valk PJ, de Bont ES, et al. Prognostic impact of white blood cell count in intermediate risk acute myeloid leukemia: relevance of mutated NPM1 and FLT3-ITD. Haematologica. 2011;96(9):1310-1317.
216. Tyner JW, Walters DK, Willis SG, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 2008;111(4):2238-2245. (Pubitemid 351451431)
217. Shimada A, Taki T, Kubota C, et al. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t (8;21) in Japan: a study of the Japanese childhood AML cooperative study group. Leukemia. 2007;21(10):2218-2219. (Pubitemid 47423822)
218. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009;360(22):2289-2301.
219. Ley TJ, Ding L, Walter MJ, et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med. 2010;363(25):2424-2433.
220. Haferlach T, Schoch C, Loffler H, et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol. 2003;21(2):256-265. (Pubitemid 46606154)
221. Weinberg OK, Seetharam M, Ren L, et al. Clinical characterization of acute myeloid leukemia with myelodysplasia-related changes as defined by the 2008 WHO classification system. Blood. 2009;113(9):1906-1908.
222. Miesner M, Haferlach C, Bacher U, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS MPN but has no independent prognostic relevance: a comparison of 408 cases classified as "AML not otherwise specified" (AML-NOS) or "AML with myelodysplasia-related changes" (AML-MRC). Blood. 2010;116(15):2742-2751.
223. Klusmann JH, Godinho FJ, Heitmann K, et al. Developmental stage-specific interplay of GATA1 and IGF signaling in fetal megakaryopoiesis and leukemogenesis. Genes Dev. 2010;24(15):1659-1672.
224. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood. 1998;92(7):2322-2333. (Pubitemid 28452973)
225. Creutzig U, Kaspers GJ. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;22(16):3432-3433. (Pubitemid 41103704)